TD5A Stock Chart & Stats
€17.00
-€0.16(-0.45%)
At close: 4:00 PM EST
€17.00
-€0.16(-0.45%)
Day’s Range― - ―
52-Week Range€8.79 - €23.09
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
€909.14M
Enterprise Value€1.61B
Total Cash (Recent Filing)€570.26M
Total Debt (Recent Filing)€734.74M
Price to Earnings (P/E)―
Beta0.02
Next Earnings
Aug 06, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding68,529,090
10 Day Avg. Volume34
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)9.53
Price to Sales (P/S)1.46
P/FCF Ratio-49.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.80Price Target Upside57.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)-0.61
Revenue Forecast (FY)€938.60M
Bulls Say, Bears Say
Bulls Say
Record Shipments And Installed‑base GrowthSustained unit placements and a growing installed base create durable demand for tandem’s consumables and services. Record shipments and double‑digit U.S. unit growth reflect expanding product adoption, improving channel traction, and a larger recurring revenue pool that supports multi‑period sales visibility.
Improving Margins And Cash GenerationMargin expansion to ~55% alongside a return to positive operating cash flow signals improving product economics and operational leverage. Durable margin gains reduce reliance on external capital over time and increase the odds of sustained profitability as revenue scales and fixed costs are absorbed.
Recurring Consumables & Platform StickinessTandem’s business model pairs durable pump hardware with high‑frequency consumables and software integrations. This installed‑base driven repeat demand and CGM/automation integrations foster revenue visibility, higher customer lifetime value, and defensibility versus one‑time device sellers.
Bears Say
Elevated Leverage And Thin Equity CushionA ~5.5x debt/equity stance materially reduces financial flexibility and raises refinancing and covenant risk if growth or margins soften. With a thinner equity base, the company is more exposed to cash‑flow volatility and may face dilution or restrictive financing terms when accessing capital markets.
Ongoing Losses; Profitability Not Yet StableDespite improvements, persistent operating and net losses mean the company still depends on margin improvement and conversion of operating cash flow into sustainable free cash flow. Continued negative or marginal FCF would force reliance on external financing, constraining strategic flexibility over the medium term.
Operational & Channel Execution RisksSupplier capacity constraints and the complex PayGo pharmacy rollout create multi‑quarter operational risk that can depress consumable revenue and customer satisfaction. Channel transitions and supplier concentration can reduce reorder predictability and slow adoption, impairing the recurring revenue profile if not fully resolved.
TD5A FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was €8.79 and its highest was €23.09 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is €909.14M.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Aug 06, 2026 which is in 28 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on May 07, 2026. The company reported -€0.261 earnings per share for the quarter, beating the consensus estimate of -€0.389 by €0.128.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.29.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 68,529,090 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -€0.261 in its last earnings report, beating expectations of -€0.389. Following the earnings report the stock price went down -9.804%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in DE:TD5A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€26.80 (57.64% Upside)
€26.80 (57.64% Upside)
Blogger Sentiment
Bullish
DE:TD5A Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.04%
12-Months-Change
Fundamentals
Return on Equity
-68.29%
Trailing 12-Months
Asset Growth
25.08%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
TD5A Company Deck
TD5A Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational and financial momentum—record shipments and sales, meaningful margin expansion, positive cash generation, a strengthened balance sheet, international go‑direct progress, and multiple product and integration milestones (Android Mobi, pregnancy clearance, FreeStyle Libre 3+ and G7 compatibility, Mobi Tubeless filing). Management acknowledged manageable near‑term headwinds from infusion set supplier shortages and the early operational friction of the PayGo pharmacy transition, plus some international timing and one‑time effects. Overall, the positive results, clear roadmap for product launches, and reaffirmed FY guidance outweigh the disclosed challenges.View all DE:TD5A earnings summariesTD5A Revenue Breakdown
74.21% U.S.
25.79% International

TD5A Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€26.80
▲(57.64% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Options Prices
Currently, No data available
---











